We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Patently unequal

22 January 2004 By Robert Cyran

Merger rumours continue to fly around the French pharmaceuticals group. The company could face generic competition on its bestselling drug this year. The effects would be disastrous.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)